a

Actana named Trailblazer in Business Analytics and Artificial Intelligence Assessment

Actana named Trailblazer in Business Analytics and Artificial Intelligence Assessment

Actana, the leader in intelligent customer engagement in the global life sciences industry, today announced it has been named a leader in the Everest Group assessment report, “Life Science and Artificial Intelligence Business Analytics.” The new report, released last month, evaluated 47 startups primarily on core capabilities and market impact, with particular consideration given to domain focus, market dynamism, product capabilities, and human capital (talent and leadership). Actana has the highest overall rating and is tied for the highest rating in both industry focus and human capital.

“Actana has been pioneering and defining the category for more than a decade,” said Derek Choi, president of Aktana. “Our exclusive focus on invigorating intelligent data for the life sciences has enabled us to transform contextual engagement in healthcare and gain recognition from important industry analysts, such as Everest Group, as well as increase market share.”

Actana has emerged as a leader in commercial life sciences analytics and artificial intelligence with over 300 deployments across more than 50 use cases. More than half of the world’s 20 largest pharmaceutical companies—including Novartis, GSK, Novo Nordisk, Merck, Sanofi, and Pfizer—rely on Aktana to coordinate and optimize custom multichannel engagement with HCPs. Aktana’s Contextual Intelligence 360 ​​platform is powered by the company’s next-generation contextual information engine, which uses AI-based optimization to predict the value of all potential customer experiences, then prioritize and recommend the next best transaction that will yield the highest return on investment.

“The focus on delivering a highly customized customer experience is driving life sciences organizations to transform their commercial technology landscape. Interestingly, startups and niche commercial technology providers have begun to gain a significant amount of mental engagement with life sciences organizations, as they are making targeted bets. To tackle the white spaces in commercial technology with their unique domain and intellectual property focused on expertise and value proposition,” according to Chnki Satija, Vice President of Everest Group. Aktana delivers an AI-based platform and suite of modular solutions to assist life sciences organizations with highly personalized customer engagement, customer journey management, and cognitive intelligence that spans the entire business function, resulting in its emergence as a leader in Life Science Business Analytics and AI Leader Evaluation. .”

Life Sciences Business Analytics and Evaluation of Everest Group’s AI Trailblazers are based on two dimensions and multiple criteria:

  • Market Impact: Measures the impact in the market by market adoption (number of customers, revenue base, annual growth), portfolio mix (diversity of customer base), value to customers based on customer feedback and other measures.
  • Core capability: measures the ability to successfully deliver products across five sub-dimensions, including vision and strategy; technological capability; flexibility and ease of deployment; participation and business model; and support.

Aktana’s modular solution allows commercial and medical teams from large organizations to rapidly scale AI software to customize, improve, and orchestrate HCP engagement across channels and teams—allowing customers to increase sales by up to 15%.

additional information:

  • Connect with Aktana on LinkedIn: linkedin.com/company/aktana
  • Follow @aktana_inc on Twitter: twitter.com/aktana_inc
  • Like Aktana on Facebook: facebook.com/aktanainc



#Actana #named #Trailblazer #Business #Analytics #Artificial #Intelligence #Assessment

Leave a Comment

Your email address will not be published. Required fields are marked *